Rationale Researchers studying behavioral and physiologic effects of d-amphetamine have explored individual response differences to the drug. Concurrently, genome-wide analyses have identified several single-nucleotide polymorphisms (SNPs) associated with these traits. Univariate methods can identify SNPs associated with behavioral and physiological traits, but multivariate analyses allow identification of clusters of related biologically relevant SNPs and behavioral components. Objectives The aim of the study was to identify clusters of related biologically relevant SNPs and behavioral components in the responses of healthy individuals to d-amphetamine using multivariate analysis. Methods Individuals (N = 375) without substance abuse histories completed surveys and detailed cardiovascular monitoring during randomized, blinded sessions: d-amphetamine (10 and 20 mg) and placebo. We applied parallel independent component analysis (Para-ICA) to data previously analyzed with univariate approaches, revealing new associations between genes and behavioral responses to damphetamine. Results Three significantly associated (p<.001) phenotypegenotype pairs emerged. The first component included physiologic measures of systolic and diastolic blood pressure (BP) and mean arterial pressure (MAP) along with SNPs in calcium and glutamatergic signaling pathways. The second associated components included the BAnger^items from the Profile of Mood States (POMS) questionnaire and the marijuana effects from the Addiction Research Center Inventory (Cuyas, Verdejo-Garcia et al.), with enriched genetic pathways involved in cardiomyopathy and MAPK signaling. The final pair included BAnxious,^BFatigue,^and BConfusion^items from the POMS questionnaire, plus functional pathways related to cardiac muscle contraction and cardiomyopathy. Conclusions Multifactorial genetic networks related to calcium signaling, glutamatergic and dopaminergic synapse function, and amphetamine addiction appear to mediate common behavioral and cardiovascular responses to d-amphetamine.
Introduction
Thus far, association studies of amphetamine response in healthy individuals have focused on candidate genes, employing univariate statistical approaches (Mattay et al. 2003 , Wardle et al. 2013 , which are typically limited by the issue of multiple comparisons, and diminish statistical power to detect subtle but Electronic supplementary material The online version of this article (doi:10.1007/s00213-015-3914-1) contains supplementary material, which is available to authorized users. important genetic effects. Thus, in the current study, we applied a novel, multivariate strategy based on parallel independent component analysis (Para-ICA; see the BMaterials and methods^section) to a previously analyzed data set.
Para-ICA is a multivariate statistical method that maximizes Bcost functions^both within and between complex feature sets (e.g., voxels in MRI scans and gene interactions). This reveals novel, biologically relevant associations that might otherwise not be detected due to small effect sizes and modest-sized sample sets , Meda et al. 2012 . In data with a large number of characteristics, Para-ICA excels at identifying and comparing the most relevant features. Para-ICA also makes more assumptions about noise, thus increasing robustness compared to previous methods.
The current reanalysis used subjective and physiological response data to d-amphetamine in healthy individuals and explored how these might be related to genetic variations among participants. It is appropriate to apply Para-ICA to investigate relationships between complex behaviors and gene-gene interactions in this high-dimensional data set.
D-amphetamine is a psychostimulant drug that acts acutely by blunting phasic dopamine release via agonist activity at D2 auto-receptors and enhancing tonic availability of dopamine and norepinephrine by blocking reuptake via membrane transporters into nerve terminals (Greene et al. 2008) . Its effects include increased alertness/vigilance/arousal, energy, mood/motivation, attention/concentration, and appetite suppression, and its side effects include hypertension, tachycardia, cardiac arrhythmias, cardiomyopathy, restlessness, dry mouth, and insomnia (Schep et al. 2010) . Although amphetamine has therapeutic value for ADHD and treating fatigue, it also has the potential for abuse and dependence (Greene et al. 2008) .
There are individual differences in amphetamine response, and both the subjective responses to acute amphetamine and amphetamine dependence are heritable (Crabbe et al. 1983 , Schilt et al. 2009 , Cherner et al. 2010 ). Some of the genetic variation is related to drug metabolism: For example, methamphetamine users exhibit differential neurocognitive deficits related to specific CYP2D6 drug metabolism-related alleles (Cherner et al. 2010) . Carriers of functional catechol-Omethyltransferase (COMT) gene variants may show differential cognitive responses to acute d-amphetamine challenge (Mattay et al. 2003 , Wardle et al. 2013 Hamidovic et al. 2010) . Although not directly related to drug challenges, individual differences in behavioral performance on executive and working memory tasks are also observed among polymorphism carriers of other genes relevant to dopaminergic function including MAOA, BDNF, and DRD4 (Fan et al. 2003 , Herrmann et al. 2007 ). To understand these individual differences, some of which may affect drug abuse susceptibility, it is important to investigate the genetic and physiological basis for subjective drug response in the general population (de Wit and Phillips 2012).
Our analysis was performed on a previously published sample that used univariate approaches, using varying sample sizes (N = 99 or 162), to focus on carefully selected, hypothesis-based candidate genes: ADORA2A, SLC6A3, BDNF, SLC6A4, CSNK1E, SLC6A2, DRD2, FAAH, COMT, and OPRM1 . Modest associations were reported, but these were difficult to replicate ). The authors also conducted a genome-wide association study (GWAS) in this population, with some modest findings (Hart et al. 2012) .
In the present analysis, we used an unsupervised multivariate approach to identify clusters of relevant interacting genes that were related in functional pathways to phenotypic components representing acute behavioral and physiologic response to d-amphetamine. Such genes could include those in processes previously associated with psychostimulant effects and/or dependence , drug side effects (e.g., dry mouth and insomnia), and those related to drug metabolism and excretion, blood-brain barrier permeability, and cardiovascular responsiveness, plus behaviorally relevant neurotransmitters, receptors, and their associated synthetic and degrading enzymes (e.g., dopamine, glutamate, and norepinephrine). For the analysis, we generated change-from-precapsule baseline scores after placebo or drug to assess genotype-phenotype relationships. Several of the subjective scales had overlapping content, and some measures of somatic effects, e.g., heart rate, might influence subjective reports. Therefore, we expected some crossover between singlenucleotide polymorphism (SNP) components associated with behavioral and with physiological components.
The Para-ICA multivariate analysis used here provides a sensitive and powerful alternative to traditional univariate analyses using single SNPs and single outcome measures. It is more powerful than univariate analysis because it examines clusters of related individual phenotypic measures in relation to clusters of related SNPs. The clustering of phenotypic measures is empirically derived from the data, and the SNPs are interpreted based on a large body of knowledge about genes involved with known biological function. Para-ICA uses these two composite clusters to reveal novel, biologically relevant associations that might otherwise not be detected. Here, we applied this robust analysis to an existing data set with acute responses to amphetamine in human volunteers.
Materials and methods

Participants
Study sample and data collection methods are detailed in previous publications (Hart et al. 2012) . Subjects were recruited and screened via modified Structured Clinical Interview for DSM-IV (SCID) (First et al. 2002) psychiatric symptom checklist (SCL-90) (Derogatis 1977) electrocardiogram, physical examination, self-reported health, and drug use history. Subjects were excluded if they were employed with night shift work, had significant medical or psychiatric conditions, smoked more than 3 cigarettes/day, consumed more than 3 cups of coffee/day, or tested positive for amphetamine, cocaine, opiates, phencyclidine (PCP), or marijuana (measured by urine toxicology: Ontrak TesTstik, Roche Diagnostic Systems Inc., Somerville, NJ).
Behavioral data collection
A total of 486 behavioral variables from the Drug Effects Questionnaire (DEQ; Chait et al. 1985) , the Addiction Research Center Inventory (Martin et al. 1971, Cuyas, VerdejoGarcia et al.) , and the Profile of Mood States (POMS; (Johanson and Uhlenhuth 1980) questionnaire were collected in addition to sex, age, education, body mass index, weekly alcohol and caffeine use, and monthly marijuana use. These included baseline responses to placebo, 10 mg d-amphetamine, and 20 mg d-amphetamine, as well as responses at five additional time points (30, 60, 90, 150 , and 180 min postdrug). In order to understand changes in these variables compared to placebo, we grouped time points 2-6 into a single measure termed the Bresponse measure.^We then created four change measures (CMs): 1CM=10 mg baseline responseplacebo baseline response; 2CM=20 mg baseline responseplacebo baseline response; 3CM=10 mg response measureplacebo response measure; and 4CM=20 mg response measure -placebo response measure. Thus, 100 final behavioral variables were created for further analysis ( Supplementary  Fig. SI ).
Genetic data collection
DNA was extracted from blood at the General Clinical Research Center at the University of Chicago. Genotyping was performed using the Affymetrix 6.0 array at the Functional Genomics Core Facility (Vanderbilt University, Memphis, TN, USA).
Genetic data processing
Prior to Para-ICA, genotyped SNPs underwent three preprocessing stages. First, quality control parameters were employed to discard data unsuitable for further analysis. Samples (both subjects and SNPs) were checked for missing data and those with missing call rates (>10 %)were excluded. A total of 375 individuals remained in the sample after excluding 6 individuals during quality control. Following this, all uninformative SNPs (constant variance) were excluded. SNPs were then checked for minor allele frequency (MAF); SNP variants with MAFs <0.1 were excluded. SNPs in linkage disequilibrium (r 2 >0.5) (in block sizes of 100 kb) were removed. Finally, SNPs were checked for Hardy-Weinberg equilibrium (in controls only) set at a threshold of p<1× 10 −5
. The above analyses were performed using PLINK (Purcell et al. 2007 ). Finally, a principal component analysis (PCA) was run using custom Matlab scripts, and the variance from the top three components was regressed out of the data to account for population stratification using an approach similar to that implemented in EIGENSTRAT (Li and Yu 2008) . All SNPs (N=178, 746) were then carried over to the next processing stage.
In order to improve interpretation, we biologically prioritized SNPs to only those contained within genes in Kyoto Encyclopedia of Genes and Genomes (KEGG) database (Mootha et al. 2003 , Kanehisa et al. 2004 , Subramanian et al. 2005 . In order to do this, we first derived genetic annotations for SNPs from the current dataset (conservatively) by using the Genome Variation Server (http://gvs.gs.washington. edu/GVSBatch137/) and restricting to SNPs within host genes (i.e., no flanking genes were used for SNP annotation). We then downloaded the complete list of KEGG genes from the molecular signatures database MSigDB (http://www. broadinstitute.org/gsea/msigdb/collections.jsp) and limited our analysis to only those that overlapped with the currently genotyped sample. This produced a biologically enriched SNP set of N=13,751 that was used as input for the Para-ICA analyses.
Parallel independent component analysis
Association mapping
The number of genetic components in the current study was estimated to be 6 and the number of components estimated for the behavioral networks was 13. Component estimation was data-driven using the standard minimum description length (MDL) criteria (Rissanen 1978) .
To investigate associations between genotype and phenotype features, Para-ICA was implemented (see Fig. 1 ) using the Fusion ICA Toolbox v2.0a (http://icatb.sourceforge.net) in Matlab 7.0 and in accordance with previously reported results (Meda et al. 2012 ). Para-ICA was designed for multimodal processing that extracts components using an entropy term based on information theory to maximize independence and enhances the interconnection by maximizing the linkage function in a joint estimation process ). The goal of Para-ICA was threefold: (a) run an ICA to extract distinct linear combinations of behavioral data (covarying phenotypic networks across subjects), (b) simultaneously run another ICA to extract distinct, linear combinations of SNP data (covarying genetic networks across subjects), and (c) maximize correlations between the derived networks from steps a and b. This process resulted in a number of components for each feature set that are variably expressed across subjects and quantified by a subject-level loading coefficient for each data type (See Fig. 1 ). The loading parameters from Para-ICA represent the weight of the overall component for each subject (Calhoun et al. 2001 , Schurz et al. 2014 . In Para-ICA, the correlation values between these loading parameters across the two feature sets are continuously updated and maximized, until a stopping criterion is reached. Comprehensive mathematical details for this methodology are also discussed in prior publications .
In order to correct for multiple comparisons in resulting behavioral/genetic correlation values, Bonferroni correction was applied based on 13 (phenotype components)×6 (genetic components)=78 comparisons yielding a corrected p value threshold of 0.05/78=0.00064. Once significant phenotypegenotype associations were identified, the corresponding phenotype and genotype networks were thresholded at a supra level |Z|>2.5 to derive significantly contributing elements from each feature set. SNPs/phenotypic variables surpassing this threshold were deemed to be contributing significantly to the overall signal of the corresponding component/network. Resulting significant genes were interpreted using a functional annotation tool, ConsensusPathDB-human (http://cpdb. molgen.mpg.de/) to visualize enriched biological networks that were associated with physiologic/behavioral responses identified within our multivariate framework. We selected KEGG from the pathway-based sets comparison option on this functional annotation tool.
Results
Overview
Participant demographics are detailed in previous publications (Hart et al. 2012 ). Response to d-amphetamine increased all scales of the DEQ, ARCI, and all but one of the POMS scales, and in a separate sparse factor analysis, their responses to factors Beuphoria,^Bdysphoria,^and Barousal^were dosedependent (Engelhardt and Stephens 2010) .
The Para-ICA reanalysis identified three significant genotype-phenotype pairs after accounting for multiple comparisons using Bonferroni correction. The top 20 most significant genes from each of the genotype components G1, G2, and G3, their Z-scores, and associated functional annotations are summarized in Table 2 . Enrichment of genes mapped to these individual SNPs yielded multiple significant pathways within the KEGG Goto 2000, Kanehisa et al. 2014) database. We report the top 10 most significant pathways associated with each component in Table 1 .
Phenotypic behavioral responses are reported as change measures (CMs), an average of all time points with baseline measures subtracted from this average. 1CM=10 mg baseline -placebo baseline; 2CM=20 mg baseline -placebo baseline; 3CM=10 mg response measure -placebo response measure; and 4CM = 20 mg response measure -placebo response measure.
Several functional pathways were enriched in all of our significant components, including dopaminergic (G1, G2, G3) and glutamatergic (G1, G2) signaling, consistent with the known mode of action of the drug. Interestingly, significant genes from our dataset (G1, G3) were also found to be over-represented in an Bamphetamine addiction^(not among top 10 pathways) KEGG pathway. As summarized earlier, multiple highly ranked genes in all three SNP components have been linked to psychostimulant use/dependence, including NRCAM in G1 (Ishiguro et al. 2006 ) and CREB5 in G2 (a modulator of CART), as well as ACTB in G3, GABRG3 in G2, and NCAM2 in G1.
Phenotype 1-genotype 1 association
The first phenotype component P1 derived by Para-ICA consisted of the physiologic measures of 3CM systolic blood pressure (BP), 3CM and 4CM measures of BP, and both 3CM and 4CM measures of mean arterial pressure (MAP). This component was negatively correlated to the first genetic component (G1; r=−.267, p=2.01e-007) ( Table 2 ) that included 211 significant SNPs (thresholded at Z=2.5). Pathway enrichment analysis indicated that G1 consisted of calcium signaling networks Bcalcium signaling pathway^and Bendocrine-regulated calcium reabsorption,^plus a Bglutamatergic synapsen etwork. The calcium signaling pathways contain SNPs associated with Ca channel subunits and function (CACNA1G, SLC8A3, SLC8A1), G-protein coupled receptor and downstream pathway genes (ADRA1A, PRKCB, ITPR1, ADCY2), and nicotinic cholinergic receptor genes (CHRNA7). The glutamatergic pathway genes within this set were related to glutamate receptors (GRIN2B, GRM1) and phospholipase C (PLCB1, PLCB2). Other KEGG processes included vascular smooth muscle contraction (that contained alpha-adrenergicrelated genes including ADRA1A), which are linked to amphetamine-mediated tachycardia and hypertension (Cruickshank and Dyer 2009) , long-term depression, gap junction, circadian entrainment, salivary secretion (amphetamine causes dry mouth), amebiasis (that contained genes relevant to the intestinal lining) and Bpathways in cancer.N etworks named Bdopaminergic synapse,^Bcholinergic synapse,^Bserotonergic synapse,^and Bamphetamine addiction^(GRIN2B, CREB5, PRKCB, CHP1, GNAS) also significantly contributed to the G1 component but were not in the top 10 most significant pathways.
Phenotype 2-genotype 2 association
Our second most significantly correlated pair (P2-G2; r= −.236, p=4.52e-006) included 4CM measures of the BAngerv ariables from the POMS questionnaire and 3CM measures from the marijuana component of the ARCI (ARCI-M) and 229 significant SNPs (thresholded at Z=2.5; see Table 2 ) that were enriched in pathways related to somatic drug responses and drug metabolism (not in top 10 pathways). Importantly, three of eleven questions chosen for ARCI-M overlap with the amphetamine sub-score. Of the non-overlapping questions, many describe effects related to salivary secretion and/or cardiovascular function, e.g., BMy mouth seems very dry^and BI notice that my heart is beating faster.^G2 pathways included dopaminergic synapse (not among top 10 pathways), Bhippocampal signaling^(not among top 10 pathways), Bvarious forms of cardiomyopathy^(hypertrophic, arrhythmogenic right ventricular, and dilated), Badherens junctionâ nd Bfocal adhesion^(not in top 10 pathways), BPI3K-Akt signaling,^Bsalivary,^and Bpancreatic secretion^(not in top 10 pathways), BMAP-kinase signaling.^Genes related to calcium channel regulation, vascular smooth muscle contraction, and AMP-activated protein kinase were enriched in these pathways as well. Networks named Bmorphine addictionâ nd Bnicotine addiction^also appeared to be significantly enriched but not among the top 10 pathways for the G2 component. The top-ranked gene in this component, CREB5, is a CART interactor (Kuhar et al. 2005 ) that has been associated with substance abuse, as well as another top gene GABRG3 (Table 2) . Amphetamine abuse has been linked to both acute and chronic cardiomyopathies (Greene et al. 2008 , Schep et al. 2010 , and acute methamphetamine damages cardiomyocyte proteins (Turdi et al. 2009 ) so the wide implication of related genes in G2 and G3 is unsurprising.
Phenotype 3-genotype 3 association
The third correlated pair P3-G3 (r=−.206, p=7.03e-005) was comprised of the BAnxious,^BFatigue,^and BConfusionî tems from POMS questionnaire. It was significantly correlated with genotype component G3, which included 208 significant SNPs (thresholded at Z=2.5) and was enriched for several functional pathways related to cardiovascular function. This included some of the same networks discussed in G1 and G2 (Bvascular smooth muscle contraction,^Bcardiac muscle contraction,^Barrhythmogenic right ventricular,^Bdilated, Table 1 List of top 10 processes using KEGG database for G1, G2, and G3 p value q value Genes implicated
G1
Calcium signaling pathway 5.96E-13 9.66E-11 ADRA1A; PLCB1; PLCB2; PRKCB; ERBB4; ADCY2; GNAS; RYR3; RYR2; CHP1; PTGFR; CACNA1G; ITPKA; SLC8A1; GNA14; CHRNA7; GNAL; SLC8A3; ITPR1; GRM1 Long-term depression 4.44E-10 3.05E-08 PLCB1; PLCB2; GRID2; PRKCB; GUCY1A2; PRKG1; GUCY1B3; PLA2G4A; ITPR1; GRM1; GNAS Circadian entrainment 5.65E-10 3.05E-08 PLCB1; PLCB2; PRKCB; ADCY2; GNAS; RYR3; RYR2; CACNA1G; GRIN2B; GUCY1A2; PRKG1; GUCY1B3; ITPR1 Salivary secretion 3.21E-09 1.30E-07 ADRA1A; PLCB1; PLCB2; ADCY2; GNAS; RYR3; PRKCB; ATP1B1; GUCY1A2; PRKG1; GUCY1B3; ITPR1 Vascular smooth muscle contraction ^and Bhypertrophic cardiomyopathies^) ( Table 1) . Additional enriched networks included focal adhesion, PI3k-Akt signaling, BMAPK signaling pathway,^calcium signaling pathway, and like G1 and G2, Bpathways in cancer.^The networks amphetamine addiction and dopaminergic synapse (discussed above) also appeared in G3 but were not among the top 10 pathways. The top SNP (ACTB) has been linked to methamphetamine-conditioned place preference (Shibasaki et al. 2011) , and another top SNP (PRKCE) has been associated with substance use and cardiovascular stress (Nikpay et al. 2012 ). We had hypothesized above that genes would be involved in functional pathways related to phenotypic components representing previously documented associations with acute behavioral and physiological responses to d-amphetamine. For the top 20 ranked genes within each SNP network, this was true for 14 SNPs in component G1, and 16 in both G2 and G3 (represented, e.g., as gene name-Gx for a particular gene comprising one of the top 20 in SNP component Gx) as follows:
Psychostimulant response, NFATC3-G1; psychostimulant dependence/addiction vulnerability, NRCAM-G1 (Ishiguro et al. 2006 , Richardson et al. 2006 ), CREB5-G2, GABRG3-G2, ACTB-G3, NCOR2-G3, and PRKCE-G3; drug metabolism and excretion, DPYD-G1; blood-brain barrier permeability, CD44-G1; cardiovascular responsiveness, NFATC3-G1, AP2A2-G1, SPTLC2-G2, RAB5A-G2, DHRS3-G2, SLC8A1-G2, CACNA2D3-G2, and ST6GALNAC3-G3; vascular contractility/endothelium, PLCB2-G1, ITGA8-G2, COLEC12-G2, PRKCQ-G3, KCNMA1-G3, PIK3C2B-G3, and PRKCE-G3; behavior-relevant neurotransmitters (dopamine), PARK2-G1, RORA-G1, and RORB-G3; glutamate, NCAM2-G1, GABA: GABRG3-G2; drug side effects (insomnia), RORA-G1 and RORB-G3; general abused substance relevance, e.g., cell adhesion processes (Ishiguro et al. 2006 , Uhl et al. 2008 ), NCAM2-G1, COL4A2-G2, and ITGA6-G2; and general brain development and/or neurotransmission, ST8SIA1-G1, ERBB4-G1, TXNDC5-G1, SPTLC2-G2, PAK7-G2, GMDS-G2, BAIAP2-G2, ACTB-G3, ORC3-G3, MAPT-G3, WASF3-G3, B3GALTL-G3, KCNK10-G3, XYLT1-G3, and DAPK1-G3.
Discussion
The current analysis used Para-ICA, a novel multivariate approach, to identify pairs of related genotype and phenotype characteristics derived from subjective and physiological responses to two d-amphetamine doses compared to placebo in healthy individuals. We demonstrate that this empirically derived approach is a useful method for examining complex behavioral and cardiovascular responses to drugs where multiple, presumably interacting genes are involved. More traditional approaches (such as GWAS) produce findings that have been hard to replicate , and require very large samples to achieve statistical significance.
Our results suggest that commonalities in d-amphetamine response may in part be explained by gene polymorphisms in several previously identified drug addiction-relevant pathways, and gene clusters related to cardiovascular function. The most significant association pair was G1-P1. Gene network G1 was negatively correlated with P1, indicating that decreased 3CM systolic BP, 3CM, and 4CM measures of diastolic BP, and 3CM and 4CM MAP measures of mean arterial pressure (MAP) associate with increased G1 loading scores. Similarly, G2-P2 and G3-P3 were negatively correlated.
Although P1 subsumed only cardiovascular responsiveness measures, whereas phenotypes 2 and 3 contained exclusively behavioral self-report items, several of these latter subjective reports contained cardiovascular responsiveness items (such as, "I noticed that my heart is beating faster^). In addition, many genes (such as those involved with many calcium and potassium channels, responsible for generating and conducting electrical impulses), are expressed both in the brain and heart (Lu et al. 1999) . This likely explains the mixture of SNPs belonging to genes identified with both The table reports significant values from a standard enrichment analysis derived from the CPDB database. Top 10 enriched KEGG process IDs are noted along with the significant genes in the current study that are involved in these processes. Uncorrected p and corresponding FDR corrected q values are also reported in this table. Gene components G1, G2, and G3 were significantly associated with phenotypic components P1, P2, and P3, respectively cardiovascular and behavioral responses in all three gene components. P1 comprised physiological drug response (HR, BP, and MAP), and the corresponding G1 contained pathways for Blong-term depression,^Bcircadian entrainment,^and calcium and glutamatergic signaling. G1's component network contains an enriched pathway for the glutamatergic synapse, including genes coding for the ionotropic glutamate receptor (GRIN2B), and SLC1A1 encoding the excitatory amino-acid transporter 2 (EAAT3), required for removing glutamate from extracellular spaces. GRIN2B has been previously identified in inter-individual responses to the amphetamine MDMA via cognitive performance (Cuyas et al. 2011) .
Metabotropic glutamate receptor (mGLUR) genes (GRM1) are also represented in G1's Bcalcium signaling^and Bglutamatergic synapse^pathways, consistent with glutamate receptor involvement in cognitive control and amphetamine processing. Both acute DA and glutamate effects in rat brain, and the alteration of long-term potentiation via glutamatergic tone and metabotropic glutamate receptors are crucial to acute responses to psychostimulant drugs and addiction (Zhang et al. 2001 , Kalivas 2009 ). The ventral medial prefrontal cortex, with abundant glutamatergic transmission, is involved in modulating bradycardic/tachycardic reflexes (Ferreira-Junior et al. 2013) . Cardiac vagal preganglionic neurons are also responsible for heart rate modulation and receive glutamatergic signaling input (Hildreth and Goodchild 2010) .
Of the top 20 genes in the G1 component (Table 2) , several have been previously linked strongly to neuronal development and addiction vulnerability (NRCAM (Ishiguro et al. 2006) , (Hodgkinson et al. 2010) 3.2732021 G1, G2, G3 genetic components, SNP single-nucleotide polymorphism a Pathways from gene card; other source of disease association and gene function is PubMed (McIntyre et al. 2010) , PRKG1 (Ishiguro et al. 2006 , Uhl et al. 2008 ) or code for proteins affecting amphetamine metabolism (DPYD, PARK2, RORA, NFATC3, GRID2). For example, NRCAM knockout mice do not develop conditioned place preference for substances (amphetamine, cocaine, morphine) that wild-type mice do (Ishiguro et al. 2006) . Dopamine 1 receptor (D1R) agonists enhance stimulatory responses and activate adenylyl cyclases, consistent with the high ranking of an adenylyl cyclase (ADCY2) gene in our G1 and G2 components; the top gene for G2 (CREB5) codes for cAMP-responsive element binding.
NCAM2
The ADCY family has been implicated in neural function and drug response (Procopio et al. 2013 ) as well as cardiac contractile response (Lipskaia et al. 2000) . ADCY2 interacts downstream with phospholipase C (PLC) signaling cascades, represented in the enriched pathways of our G1 component (PLCB1, PLCB2). PLC hydrolyses phosphatidylinositol 4,5-biphosphate (PIP 2 ) to create inositol 1,4,5-triphosphate receptor (IP3). The gene coding for IP3 receptor type 1 (ITPR1) is enriched in pathways of the G1 and G2 component.
A recent GWAS report of comorbid depression and alcoholism subjects (from the Consortium on the Genetics of Alcoholism, COGA) reported clusters of potential riskconferring alleles similar to those described here (Edwards et al. 2012 ) including glutamatergic genes (GRIN2C (Edwards et al. 2012) , GRIN2B (G1,G2), GRIN2A (G3; Edwards et al. 2012) , GRIA1 (Edwards, Aliev et al.) , GRIA4 (Edwards, Aliev et al.) , and GRM1 (G1,G2)). CTNNA2 is enriched in G2 and G3, while CTNNA3 is enriched in pathways from our G2 component. CTNNA2 has been identified in a large study of risk-taking propensity and excitement seeking (Terracciano et al. 2011 ). Thus, there may be commonalities and functional gene networks underlying multiple types of substance abuse.
Enriched pathways in the G2 component include BMAPK signaling,^BPI3K/Akt signaling,^Bsalivary secretion,B hypertrophic cardiomyopathy,^Bdilated cardiomyopathy,â rrhythmogenic right ventricular cardiomyopathy, and circadian entrainment (Table 1) . Protein expression related to cardiovascular function would logically affect both subjective drug effects and physiological responses, as they involve generating, amplifying, and transmitting cellular electrical signals in both the heart and CNS. Heart rate increase in response to drug's stimulant properties has been reported as a risk factor for substance abuse (Conrod et al. 2001 ). Li and colleagues ) surveyed 1500 human addiction-related genes to identify molecular pathways significantly enriched for all four major classes of addictive drugs . The authors then narrowed these genes to those supported by two or more studies, and finally to gene pathways enriched by these genes as compared to the whole genome. Among the most significant pathways identified were the MAPK (G2, G3) and calcium signaling (G1, G2, and G3) pathways along with the gap junction (G1). MAPK is also cited in relation to amphetamine exposure by Wang et al. (2011) and Akt by Chen et al. (2009) .
Salivary secretion decreases with amphetamine (Gotrick et al. 2009 ), leading to complaints of dry mouth, and in part contributing to dental damage in chronic amphetamine abuse. DHRS3 is a top gene in the G2 component and is related to myocardial formation. The deletion or mutation of other top G2 genes results in cardiac failure, arrhythmia (SLC8A1), and stroke (PRKCH, COL4A2).
Another top-ranked gene appearing in G2 codes for the GABA-receptor subunit, GABRG3, identified as conferring genetic risk for alcoholism/alcohol withdrawal symptoms in COGA (Edenberg and Foroud 2006) . This gene also appeared within our functional networks named morphine addiction and nicotine addiction.
The G3 component includes enriched pathways previously discussed in G1 and G2 in addition to pathways named focal adhesion, vascular smooth muscle contraction, and cardiac muscle contraction. Adhesion molecules likely play an important role in methamphetamine risk (Uhl et al. 2008 ).
This component contained multiple genes associated with neuronal development and with vascular smooth muscle contraction. Two among the top four, ACTB (Shibasaki et al. 2011) and NCOR2, are known to be associated with amphetamine and cocaine dependence, respectively; the second emerged as a gene important in cocaine dependence risk study (Gelernter et al. 2013) . Several cardiac genes in the G3 component are involved in smooth muscle function through calcium and potassium channel-related pathways (KCNK10, KCNMA1, PIK3C2B, PRKCE, ST6GALNAC3). PRKCE has also been implicated as a risk gene for substance use, and hyperactive stress response. Animals with PRKCE dysfunction show increased sensitivity to alcohol and consume less alcohol than wild-type mice (Choi et al. 2002) Genes in the CACNA family (CACNG3, CACNA2D4, CACNA1A, CACNA1E, CACNA1G, CACNA2D3, CACN A2D1, CACNB2) were represented in the cardiac muscle contraction pathway and highly correlated with behavioral components in our G3 component. CACNA1C and CACNA2D4 deletion has been implicated in bipolar disorder and schizophrenia susceptibility (Roussos et al. 2013) . Similarly, a nicotinic cholinergic receptor gene enriched in pathways of G1 (CHRNA7) has been associated with schizophrenia (Freedman 2013) . Amphetamine use is associated with symptomatic schizophrenia-like illnesses, likely associated with excessive dopamine release (Bramness et al. 2012) .
In general, Para-ICA identified gene components related to drug use and abuse such as dopaminergic and glutamatergic signaling. Our results indicate a possible multiloci genetic component encompassing individual genes playing crucial roles in drug response that may be markers for substance abuse susceptibility. Although we were unable to replicate the majority of previously reported genetic findings from the same subjects in univariate analyses (Hamidovic et al. 2010 , Wardle et al. 2013 , these initially published findings were also not replicated in an expanded subject sample ).
Limitations
We recognize that our results are unreplicated and that our analysis does not cover all genes or all neural genes. Our study is limited to functional annotation software categories and gene ontologies that are works-in-progress (Khatri et al. 2012) and can contain functional annotation data based on prediction rather than experimental evidence. In addition, each of the pathway databases could have a inherent bias associated with them with respect to genes available within them given the nature of their initial field of inception. While our genetic pathways reflect the most current knowledge to date, the particular nomenclature may be transient. Our analysis also depends on SNPs with allele frequencies greater than 0.1 and restricting to KEGG-related genes. The SNPs genotyped on the arrays may not capture some functional variants that are not in strong linkage disequilibrium.
Para-ICA should be considered for future analyses of behavioral-genetic relationships in individual drug responses. This multivariate analysis strategy compares relationships within and between two composite clusters and identified several plausible network associations between d-amphetamine response and genetic variation. Both phenotypic and genotypic findings were generally predictable from known clinical acute behavioral and cardiovascular amphetamine effects and corresponding genes associated with related physiological brain and cardiovascular processes, respectively, as well as genes associated with longer-term psychostimulant abuse/ dependence.
